Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Posts 16-Percent Rise in Q3 Sales as Losses Swell 18 Percent

This update includes the fact that Cepheid ended the quarter with $82.2 million in marketable securities as well as $16.2 million in cash and equivalents.
NEW YORK (GenomeWeb News) — Cepheid today said third-quarter revenues increased 16 percent as R&D spending rose 17 percent and net loss increased 18 percent.
Total receipts for the three months ended Sept. 30 increased to $23.8 million from $20.4 million year over year.
The company said sales of clinical products were up 135 percent to $5.8 million and sales of its industrial products climbed 28 percent to $4.8 million.
However, sales in its bio-threat products fell 7 percent to $12.1 million from $13 million a year ago, which Cepheid said was partly due to the completion of contracts with the USPS.
R&D spending increased to $5.6 million from $4.8 million year over year.
The company said net losses increased to $3.9 million from $3.3 million in the year-ago period.
Cepheid said it had around $16.2 million in cash and cash equivalents and $82.2 million in marketable securities as of Sept. 30.
The company said it expects to generate between $83 million and $86 million in sales in 2006.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.